Visitors are not permitted at Sunnybrook. Read more »

Hospital  >  News & media  >  News

Notch Therapeutics a new company with a revolutionary allogeneic ('off the shelf') T cell technology

November 5, 2019


Aligned with our vision to invent the future of health care, Sunnybrook – along with co-founders CCRM, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and investor Lumira Ventures – has created Notch Therapeutics, a new company in the emerging field of T cell therapy.

Notch looks to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making high quality and clinically robust T cell therapies.